In Silico Analysis Highlights Potential Predictive Indicators Associated with Secondary Progressive Multiple Sclerosis

被引:0
|
作者
Calabro, Marco [1 ]
Lui, Maria [1 ]
Mazzon, Emanuela [1 ]
D'Angiolini, Simone [1 ]
机构
[1] IRCCS Ctr Neurolesi Bonino Pulejo, Via Provinciale Palermo, I-98124 Messina, Italy
关键词
secondary progressive multiple sclerosis; transcriptomic analysis; blood samples; brain samples; biomarkers; AUTOREACTIVE T-CELLS; BLOOD-BRAIN-BARRIER; GENE-EXPRESSION; NATURAL-HISTORY; CYSTATIN-F; NK CELLS; ACTIVATION; CLUSTERIN; AUTOIMMUNE; DYSREGULATION;
D O I
10.3390/ijms25063374
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple sclerosis (MS) is a complex inflammatory disease affecting the central nervous system. Most commonly, it begins with recurrent symptoms followed by partial or complete recovery, known as relapsing-remitting MS (RRMS). Over time, many RRMS patients progress to secondary progressive MS (SPMS), marked by gradual symptom deterioration. The factors triggering this transition remain unknown, lacking predictive biomarkers. This study aims to identify blood biomarkers specific to SPMS. We analyzed six datasets of SPMS and RRMS patients' blood and brain tissues, and compared the differential expressed genes (DEGs) obtained to highlight DEGs reflecting alterations occurring in both brain and blood tissues and the potential biological processes involved. We observed a total of 38 DEGs up-regulated in both blood and brain tissues, and their interaction network was evaluated through network analysis. Among the aforementioned DEGs, 21 may be directly involved with SPMS transition. Further, we highlighted three biological processes, including the calcineurin-NFAT pathway, related to this transition. The investigated DEGs may serve as a promising means to monitor the transition from RRMS to SPMS, which is still elusive. Given that they can also be sourced from blood samples, this approach could offer a relatively rapid and convenient method for monitoring MS and facilitating expedited assessments.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Secondary progressive multiple sclerosis - clinical course and potential predictive factors
    Pokryszko-Dragan, Anna
    Gruszka, Ewa
    Bilinska, Matgorzata
    Dubik-Jezierzanska, Marta
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2008, 42 (01) : 6 - 11
  • [2] Diagnosis and management of secondary-progressive multiple sclerosis: time for change
    Oh, Jiwon
    Alikhani, Katayoun
    Bruno, Tania
    Devonshire, Virginia
    Giacomini, Paul S.
    Giuliani, Fabrizio
    Nakhaipour, Hamid R.
    Schecter, Robyn
    Larochelle, Catherine
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2019, 9 (06) : 301 - 317
  • [3] Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis
    Sellebjerg, Finn
    Cadavid, Diego
    Steiner, Deborah
    Maria Villar, Luisa
    Reynolds, Richard
    Mikol, Daniel
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (01) : 31 - 43
  • [4] Defining secondary progressive multiple sclerosis
    Lorscheider, Johannes
    Buzzard, Katherine
    Jokubaitis, Vilija
    Spelman, Tim
    Havrdova, Eva
    Horakova, Dana
    Trojano, Maria
    Izquierdo, Guillermo
    Girard, Marc
    Duquette, Pierre
    Prat, Alexandre
    Lugaresi, Alessandra
    Grand'Maison, Francois
    Grammond, Pierre
    Hupperts, Raymond
    Alroughani, Raed
    Sola, Patrizia
    Boz, Cavit
    Pucci, Eugenio
    Lechner-Scott, Jeanette
    Bergamaschi, Roberto
    Oreja-Guevara, Celia
    Iuliano, Gerardo
    Van Pesch, Vincent
    Granella, Franco
    Ramo-Tello, Cristina
    Spitaleri, Daniele
    Petersen, Thor
    Slee, Mark
    Verheul, Freek
    Ampapa, Radek
    Amato, Maria Pia
    McCombe, Pamela
    Vucic, Steve
    Sanchez Menoyo, Jose Luis
    Cristiano, Edgardo
    Barnett, Michael H.
    Hodgkinson, Suzanne
    Olascoaga, Javier
    Laura Saladino, Maria
    Gray, Orla
    Shaw, Cameron
    Moore, Fraser
    Butzkueven, Helmut
    Kalincik, Tomas
    BRAIN, 2016, 139 : 2395 - 2405
  • [5] Early predictors of conversion to secondary progressive multiple sclerosis
    Barzegar, Mahdi
    Najdaghi, Soroush
    Afshari-Safavi, Alireza
    Nehzat, Nasim
    Mirmosayyeb, Omid
    Shaygannejad, Vahid
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 54
  • [6] Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis
    Healy, Brian C.
    Zurawski, Jonathan
    Chitnis, Tanuja
    Weiner, Howard L.
    Glanz, Bonnie, I
    QUALITY OF LIFE RESEARCH, 2022, 31 (06) : 1799 - 1805
  • [7] Cognitive reserve in secondary progressive multiple sclerosis
    Sumowski, James F.
    Chiaravalloti, Nancy
    Leavitt, Victoria M.
    DeLuca, John
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (10) : 1454 - 1458
  • [8] Interferon beta for secondary progressive multiple sclerosis
    La Mantia, Loredana
    Vacchi, Laura
    Di Pietrantonj, Carlo
    Ebers, George
    Rovaris, Marco
    Fredrikson, Sten
    Filippini, Graziella
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (01):
  • [9] Secondary Progressive Multiple Sclerosis: Definition and Measurement
    Plantone, Domenico
    De Angelis, Floriana
    Doshi, Anisha
    Chataway, Jeremy
    CNS DRUGS, 2016, 30 (06) : 517 - 526
  • [10] Secondary Progressive Multiple Sclerosis: Definition and Measurement
    Domenico Plantone
    Floriana De Angelis
    Anisha Doshi
    Jeremy Chataway
    CNS Drugs, 2016, 30 : 517 - 526